(A and B) ChIP-qPCR analysis of HSF2 binding to the indicated KSHV genomic regions expressed as % of input in KSHV infected latent (A) and lytic (B) cells. by Lorenza Cutrone (21144285)

(A) Confocal representative images and (B) quantification of the H3me3K4 integrated intensity in n > 100 cells in iSLK.219 either latent or induced to the lytic cycle with doxycycl... by Lorenza Cutrone (21144285)

<b>The loss of insulin-positive cell clusters precedes the decrease of islet frequency and beta cell area in type 1 diabetes</b> by Denise M. Drotar (21679539)

“…Moreover, changes in endocrine composition also occurred in mAAb+ donors, including a significant decrease in the INS+ islet fraction. …”

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

Raw data of the charts in Fig 5. by Kam Pui Tam (19746865)

“…Concurrently, venetoclax inhibited Bcl-2 upregulated by either LMP-1 or EBNA-3C. Bort/venetoclax decreased the expression of phosphorylated p65 and Bcl-2 at serine 70 thereby suppressing the NF-κB signaling pathway and promoting apoptosis, respectively. …”

Antibodies used in western blot analysis. by Kam Pui Tam (19746865)

“…Concurrently, venetoclax inhibited Bcl-2 upregulated by either LMP-1 or EBNA-3C. Bort/venetoclax decreased the expression of phosphorylated p65 and Bcl-2 at serine 70 thereby suppressing the NF-κB signaling pathway and promoting apoptosis, respectively. …”

Raw data of the charts in Fig 3. by Kam Pui Tam (19746865)

“…Concurrently, venetoclax inhibited Bcl-2 upregulated by either LMP-1 or EBNA-3C. Bort/venetoclax decreased the expression of phosphorylated p65 and Bcl-2 at serine 70 thereby suppressing the NF-κB signaling pathway and promoting apoptosis, respectively. …”

Raw data of the charts in Fig 1. by Kam Pui Tam (19746865)

“…Concurrently, venetoclax inhibited Bcl-2 upregulated by either LMP-1 or EBNA-3C. Bort/venetoclax decreased the expression of phosphorylated p65 and Bcl-2 at serine 70 thereby suppressing the NF-κB signaling pathway and promoting apoptosis, respectively. …”

Raw data of the charts in Fig 6. by Kam Pui Tam (19746865)

“…Concurrently, venetoclax inhibited Bcl-2 upregulated by either LMP-1 or EBNA-3C. Bort/venetoclax decreased the expression of phosphorylated p65 and Bcl-2 at serine 70 thereby suppressing the NF-κB signaling pathway and promoting apoptosis, respectively. …”

Raw data of the charts in Fig 2. by Kam Pui Tam (19746865)

“…Concurrently, venetoclax inhibited Bcl-2 upregulated by either LMP-1 or EBNA-3C. Bort/venetoclax decreased the expression of phosphorylated p65 and Bcl-2 at serine 70 thereby suppressing the NF-κB signaling pathway and promoting apoptosis, respectively. …”

Response distributions for the questions that represent the latent variable ‘cautious sexual attitudes’. by Abigail A. Lee (19935335)

Fit statistics for CFA analysis of the latent variable “intent to vaccinate against HPV”. by Abigail A. Lee (19935335)

Data Sheet 1_Persistent lymphopenia after kidney transplantation: increased mortality and decreased homeostatic mechanisms.docx by Yun Liang (383275)

“…</p>Discussion<p>We conclude that persistent lymphopenia might be partially due to impaired homeostatic mechanisms in T, B and NK cells and might be a simple, useful biomarker for individualizing patient management.…”

Participant retention flowchart. by Carolin Oetzmann (11397968)

“…We identified a 4-class solution: (1) severe with appetite decrease, (2) severe with appetite increase, (3) moderate severity and (4) low severity. …”

Posterior distribution of the effect of the latent variable on the probability of seeking traditional remedies after a potential dog bite indicates a decreased likelihood of individuals seeking traditional remedies. by Philip P. Mshelbwala (11278898)

“…<p>Posterior distribution of the effect of the latent variable on the probability of seeking traditional remedies after a potential dog bite indicates a decreased likelihood of individuals seeking traditional remedies.…”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

Subjects: